A-549Homo sapiens (Human)Cancer cell line
Also known as: A 549, A549, NCI-A549, A549/ATCC, A549 ATCC, A549ATCC, hA549, A594 (In abstract of PubMed 18227028.), A59
A549
Quick Overview
Human lung adenocarcinoma cell line used in cancer research.
Detailed Summary
Research Applications
Key Characteristics
Basic Information
| Database ID | CVCL_0023 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Lung[UBERON:UBERON_0002048] |
Donor Information
| Age | 58 |
|---|---|
| Age Category | Adult |
| Sex | Male |
| Race | caucasian |
Disease Information
| Disease | Lung adenocarcinoma |
|---|---|
| Lineage | Lung |
| Subtype | Lung Adenocarcinoma |
| OncoTree Code | LUAD |
DepMap Information
| Source Type | ATCC |
|---|---|
| Source ID | ACH-000681_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| MutationSimple | KRAS | p.Gly12Ser (c.34G>A) | Unspecified | - | PubMed=27004849 |
| MutationSimple | STK11 | p.Gln37Ter (c.109C>T) | Homozygous | - | from parent cell line A549/DDP |
| MutationNone reported | TP53 | - | - | - | PubMed=19787792 |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Loading gene expression data...
Publications
Variable expression on lung cancer cell lines of HLA-A2-binding MAGE-3 peptide recognized by cytotoxic T lymphocytes.
Shibuya A., Tsuji T., Sekiguchi S., Nakayama E.
Int. J. Oncol. 12:1103-1109(1998).
Increased glucose influx and glycogenesis in lung cancer cells surviving after irradiation.
Koukourakis M.I.
Int. J. Radiat. Biol. 99:692-701(2023).
Pan-cancer proteomic map of 949 human cell lines.";
Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Cancer Cell 40:835-849.e8(2022).
Proteomic and ultrastructural analysis of Clara cell and type II alveolar epithelial cell-type lung cancer cells.
Hou W.-L., Chang M., Liu X.-F., Hu L.-S., Hua S.-C.
Transl. Cancer Res. 9:565-576(2020).
High-throughput sequencing for species authentication and contamination detection of 63 cell lines.
Moniwa M.
Sci. Rep. 11:21657-21657(2021).
The cancer SENESCopedia: a delineation of cancer cell senescence.";
Leite de Oliveira R., Wessels L.F.A., Bernards R.
Cell Rep. 36:109441.1-109441.22(2021).
Comparative proteogenomics profiling of non-small and small lung carcinoma cell lines using mass spectrometry.
Wu J.-Y., Hao Z.-F., Ma C., Li P.-F., Dang L.-Y., Sun S.-S.
PeerJ 8:e8779.1-e8779.19(2020).
Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
Sellers W.R., Gygi S.P.
Cell 180:387-402.e16(2020).
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Sellers W.R.
Nature 569:503-508(2019).
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.
Nature 568:511-516(2019).
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
Cancer Res. 79:1263-1273(2019).
Evaluation of NCI-7 cell line panel as a reference material for clinical proteomics.
Shah P., Whiteley G.R., Zhang H.
J. Proteome Res. 17:2205-2215(2018).
Chemistry-first approach for nomination of personalized treatment in lung cancer.
Posner B.A., Minna J.D., Kim H.S., White M.A.
Cell 173:864-878.e29(2018).
Identification of various cell culture models for the study of Zika virus.
Himmelsbach K., Hildt E.
World J. Virol. 7:10-20(2018).
Deletion of adipose triglyceride lipase links triacylglycerol accumulation to a more-aggressive phenotype in A549 lung carcinoma cells.
Thallinger G.G., Nomura D.K., Schittmayer M., Birner-Gruenberger R.
J. Proteome Res. 17:1415-1425(2018).
Differential effector engagement by oncogenic KRAS.";
McCormick F.
Cell Rep. 22:1889-1902(2018).
Cisplatin resistance in non-small cell lung cancer cells is associated with an abrogation of cisplatin-induced G2/M cell cycle arrest.
Frotschl R.
PLoS ONE 12:E0181081-E0181081(2017).
An optimized shotgun strategy for the rapid generation of comprehensive human proteomes.
Lindbjerg Andersen C., Nielsen M.L., Olsen J.V.
Cell Syst. 4:587-599.e4(2017).
Non-small-cell lung cancer cell lines A549 and NCI-H460 express hypoxanthine guanine phosphoribosyltransferase on the plasma membrane.
Robison R.A., O'Neill K.L.
Onco Targets Ther. 10:1921-1932(2017).
Characterization of human cancer cell lines by reverse-phase protein arrays.
Liang H.
Cancer Cell 31:225-239(2017).
Transcriptome sequencing reveals key pathways and genes associated with cisplatin resistance in lung adenocarcinoma A549 cells.
Fang Y.-N., Zhang C., Wu T., Wang Q., Liu J.-H., Dai P.-G.
PLoS ONE 12:E0170609-E0170609(2017).
A map of mobile DNA insertions in the NCI-60 human cancer cell panel.
Gnanakkan V.P., Cornish T.C., Boeke J.D., Burns K.H.
Mob. DNA 7:20.1-20.11(2016).
A landscape of pharmacogenomic interactions in cancer.";
Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
Cell 166:740-754(2016).
Long non-coding RNA expression profiling in the NCI60 cancer cell line panel using high-throughput RT-qPCR.
Vandesompele J.
Sci. Data 3:160052-160052(2016).
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Loewer M., Sahin U., Castle J.C.
Genome Med. 7:118.1-118.7(2015).
Rapid high-pH reverse phase stagetip for sensitive small-scale membrane proteomic profiling.
Chen Y.-J.
Anal. Chem. 87:12016-12023(2015).
Mining missing membrane proteins by high-pH reverse-phase stagetip fractionation and multiple reaction monitoring mass spectrometry.
Nesvizhskii A.I., Sung T.-Y., Chen Y.-J.
J. Proteome Res. 14:3658-3669(2015).
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
Golub T.R., Root D.E., Hahn W.C.
Sci. Data 1:140035-140035(2014).
A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.
Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.
OncoImmunology 3:e954893.1-e954893.12(2014).
A resource for cell line authentication, annotation and quality control.
Neve R.M.
Nature 520:307-311(2015).
A comprehensive transcriptional portrait of human cancer cell lines.
Settleman J., Seshagiri S., Zhang Z.-M.
Nat. Biotechnol. 33:306-312(2015).
Evaluation of A549 as a new vaccine cell substrate: digging deeper with massively parallel sequencing.
Shabram P., Kolman J.L.
PDA J. Pharm. Sci. Technol. 68:639-650(2014).
Aberrant methylation and silencing of IRF8 expression in non-small cell lung cancer.
Shibata H., Ito T., Baba Y., Baba H.
Oncol. Lett. 8:1025-1030(2014).
High resolution copy number variation data in the NCI-60 cancer cell lines from whole genome microarrays accessible through CellMiner.
Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C.
PLoS ONE 9:E92047-E92047(2014).
Detection of viral proteins in human cells lines by xeno-proteomics: elimination of the last valid excuse for not testing every cellular proteome dataset for viral proteins.
Chernobrovkin A.L., Zubarev R.A.
PLoS ONE 9:E91433-E91433(2014).
The metabolic demands of cancer cells are coupled to their size and protein synthesis rates.
Hirshfield K.M., Oltvai Z.N., Vazquez A.
Cancer Metab. 1:20.1-20.13(2013).
Reconstructing targetable pathways in lung cancer by integrating diverse omics data.
Cao X.-H., Nesvizhskii A.I., Chinnaiyan A.M.
Nat. Commun. 4:2617.1-2617.13(2013).
Global proteome analysis of the NCI-60 cell line panel.";
Wilhelm M., Kuster B.
Cell Rep. 4:609-620(2013).
The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.
Simon R.M., Doroshow J.H., Pommier Y., Meltzer P.S.
Cancer Res. 73:4372-4382(2013).
Simulated microgravity alters the metastatic potential of a human lung adenocarcinoma cell line.
Yuan M., Wang J.-F., Li T.-Z., Liu C.-T.
In Vitro Cell. Dev. Biol. Anim. 49:170-177(2013).
Dynamic DNA methylation across diverse human cell lines and tissues.
Crawford G.E., Absher D.M., Wold B.J., Myers R.M.
Genome Res. 23:555-567(2013).
Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.
Heymach J.V.
Cancer Discov. 2:798-811(2012).
Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation.
Kafri R., Kirschner M.W., Clish C.B., Mootha V.K.
Science 336:1040-1044(2012).
Antiproliferative action of metformin in human lung cancer cell lines.
Tanabe N., Iwama A., Yokosuka O., Tatsumi K.
Oncol. Rep. 28:8-14(2012).
Effects of alpha-particle radiation on microRNA responses in human cell-lines.
Chauhan V., Howland M., Wilkins R.C.
Open Biochem. J. 6:16-22(2012).
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
Nature 483:603-607(2012).
Identification of cancer cell-line origins using fluorescence image-based phenomic screening.
Yoon C.N., Chang Y.-T.
PLoS ONE 7:E32096-E32096(2012).
Mass homozygotes accumulation in the NCI-60 cancer cell lines as compared to HapMap trios, and relation to fragile site location.
Ruan X.-Y., Kocher J.-P.A., Pommier Y., Liu H.-F., Reinhold W.C.
PLoS ONE 7:E31628-E31628(2012).
JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.
Kong D.-X., Yamori T.
Bioorg. Med. Chem. 20:1947-1951(2012).
Lack of AKT activation in lung cancer cells with EGFR mutation is a novel marker of cetuximab sensitivity.
Igishi T., Burioka N., Nanba E., Shimizu E.
Cancer Biol. Ther. 13:369-378(2012).
Human tumor cell strains defective in the repair of alkylation damage.
Mattern M.R.
Carcinogenesis 1:21-32(1980).
Comparative proteomic analysis of eleven common cell lines reveals ubiquitous but varying expression of most proteins.
Geiger T., Wehner A., Schaab C., Cox J., Mann M.
Mol. Cell. Proteomics 11:M111.014050-M111.014050(2012).
Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance.
Ambudkar S.V., Gottesman M.M.
Proc. Natl. Acad. Sci. U.S.A. 108:18708-18713(2011).
Phosphoproteome profile of human lung cancer cell line A549.";
Jia H.-L., He J.-X., He Q.-Y.
Mol. Biosyst. 7:472-479(2011).
Prevalence of human papillomavirus 16/18/33 infection and p53 mutation in lung adenocarcinoma.
Iwakawa R., Kohno T., Enari M., Kiyono T., Yokota J.
Cancer Sci. 101:1891-1896(2010).
Characterization of two human lung adenocarcinoma cell lines by reciprocal chromosome painting.
Peng K.-J., Wang J.-H., Su W.-T., Wang X.-C., Yang F.-T., Nie W.-H.
Dong Wu Xue Yan Jiu 31:113-121(2010).
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Haber D.A.
Cancer Res. 70:2158-2164(2010).
Signatures of mutation and selection in the cancer genome.";
Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Nature 463:893-898(2010).
Comparative proteomic analysis of lung cancer cell line and lung fibroblast cell line.
Chiablaem K., Svasti J., Sangvanich P.
Cancer Genomics Proteomics 6:229-237(2009).
Lysine acetylation targets protein complexes and co-regulates major cellular functions.
Walther T.C., Olsen J.V., Mann M.
Science 325:834-840(2009).
A gene-alteration profile of human lung cancer cell lines.";
Montuenga L.M., Minna J.D., Yokota J., Sanchez-Cespedes M.
Hum. Mutat. 30:1199-1206(2009).
DNA fingerprinting of the NCI-60 cell line panel.";
Chanock S.J., Weinstein J.N.
Mol. Cancer Ther. 8:713-724(2009).
The SRY-HMG box gene, SOX4, is a target of gene amplification at chromosome 6p in lung cancer.
Cigudosa J.C., Lazo P.A., Sanchez-Cespedes M.
Hum. Mol. Genet. 18:1343-1352(2009).
Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.
Zhou X.-M., Gygi S.P., Gu T.-L., Polakiewicz R.D., Rush J., Comb M.J.
Cell 131:1190-1203(2007).
Cytokine production of lung cancer cell lines: correlation between their production and the inflammatory/immunological responses both in vivo and in vitro.
Yasumoto K.
Cancer Sci. 98:1048-1054(2007).
Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification.
Takada M., Fukuoka M., Nakagawa K.
Cancer Res. 67:2046-2053(2007).
Gene expression profiles in asbestos-exposed epithelial and mesothelial lung cell lines.
Kaski S., Hollmen J., Anttila S., Kinnula V.L., Knuutila S.
BMC Genomics 8:62.1-62.14(2007).
Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.
Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.
Mol. Cancer Ther. 5:2606-2612(2006).
Determinants of cisplatin and irinotecan activities in human lung adenocarcinoma cells: evidence of cisplatin accumulation and topoisomerase I activity.
Tabata M., Ueoka H., Tanimoto M.
In Vivo 19:717-721(2005).
p53-defective tumors with a functional apoptosome-mediated pathway: a new therapeutic target.
Tomoda H., Yamori T., Tsuruo T.
J. Natl. Cancer Inst. 97:765-777(2005).
HLA class I and II genotype of the NCI-60 cell lines.";
Morse H.C. 3rd, Stroncek D., Marincola F.M.
J. Transl. Med. 3:11.1-11.8(2005).
Frequent silencing of DBC1 is by genetic or epigenetic mechanisms in non-small cell lung cancers.
Hirohashi S., Inazawa J., Imoto I.
Hum. Mol. Genet. 14:997-1007(2005).
TERC identified as a probable target within the 3q26 amplicon that is detected frequently in non-small cell lung cancers.
Yokoi S., Yasui K., Iizasa T., Imoto I., Fujisawa T., Inazawa J.
Clin. Cancer Res. 9:4705-4713(2003).
RASSF1A gene inactivation in non-small cell lung cancer and its clinical implication.
Mitsudomi T.
Int. J. Cancer 106:45-51(2003).
Identification of microsatellite instability and mismatch repair gene mutations in breast cancer cell lines.
Santibanez-Koref M.F., Schlag P.M., Scherneck S.
Genes Chromosomes Cancer 37:29-35(2003).
Differential proteomic analysis of human lung adenocarcinoma cell line A-549 and of normal cell line HBE.
Liang S.-P.
Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao 34:50-56(2002).
Molecular cytogenetic analysis of non-small cell lung carcinoma by spectral karyotyping and comparative genomic hybridization.
Luk C., Tsao M.-S., Bayani J., Shepherd F.A., Squire J.A.
Cancer Genet. Cytogenet. 125:87-99(2001).
Mutation and expression of the DCC gene in human lung cancer.";
Yokota J.
Neoplasia 2:300-305(2000).
Systematic variation in gene expression patterns in human cancer cell lines.
Botstein D., Brown P.O.
Nat. Genet. 24:227-235(2000).
Comprehensive analysis of p53 gene mutation characteristics in lung carcinoma with special reference to histological subtypes.
Fujita T., Kiyama M., Tomizawa Y., Kohno T., Yokota J.
Int. J. Oncol. 15:927-934(1999).
Establishment of a drug sensitivity panel using human lung cancer cell lines.
Kohara H., Harada M.
Acta Med. Okayama 53:67-75(1999).
Coincidental alterations of p16INK4A/CDKN2 and other genes in human lung cancer cell lines.
Fujishita T., Mizushima Y., Kashii T., Kobayashi M.
Anticancer Res. 18:1537-1542(1998).
Paracrine effects of hepatocyte growth factor/scatter factor on non-small-cell lung carcinoma cell lines.
Yi S., Chen J.-R., Viallet J., Schwall R.H., Nakamura T., Tsao M.-S.
Br. J. Cancer 77:2162-2170(1998).
Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice.
Old L.J., Schreiber R.D.
Proc. Natl. Acad. Sci. U.S.A. 95:7556-7561(1998).
Cell growth curves for different cell lines and their relationship with biological activities.
Rubio-Pino J.L.
Int. J. Biotechnol. Mol. Biol. Res. 4:60-70(2013).
Tissue typing of cells in culture. III. HLA antigens of established human cell lines. Attempts at typing by the mixed hemadsorption technique.
Espmark J.A., Ahlqvist-Roth L., Sarne L., Persson A.
Tissue Antigens 11:279-286(1978).
A continuous tumor-cell line from a human lung carcinoma with properties of type II alveolar epithelial cells.
Lieber M.M., Smith B.T., Szakal A., Nelson-Rees W.A., Todaro G.J.
Int. J. Cancer 17:62-70(1976).
One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice.
Fogh J., Fogh J.M., Orfeo T.
J. Natl. Cancer Inst. 59:221-226(1977).
Human melanoma cells have both nerve growth factor and nerve growth factor-specific receptors on their cell surfaces.
Sherwin S.A., Sliski A.H., Todaro G.J.
Proc. Natl. Acad. Sci. U.S.A. 76:1288-1292(1979).
Absence of HeLa cell contamination in 169 cell lines derived from human tumors.
Fogh J., Wright W.C., Loveless J.D.
J. Natl. Cancer Inst. 58:209-214(1977).
Cell line A549: a model system for the study of alveolar type II cell function.
Smith B.T.
Am. Rev. Respir. Dis. 115:285-293(1977).
Analysis of established human carcinoma cell lines for lymphoreticular-associated membrane receptors.
Kerbel R.S., Pross H.F., Leibovitz A.
Int. J. Cancer 20:673-679(1977).
p53 mutations, ras mutations, and p53-heat shock 70 protein complexes in human lung carcinoma cell lines.
Gerwin B.I., Harris C.C.
Cancer Res. 51:4090-4096(1991).
Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines.
Gray-Goodrich M., Campbell H., Mayo J.G., Boyd M.R.
J. Natl. Cancer Inst. 83:757-766(1991).
Metabolic activation of 4-ipomeanol in human lung, primary pulmonary carcinomas, and established human pulmonary carcinoma cell lines.
Adelberg S., Czerwinski M.J., McMahon N.A., Eggleston J.C., Boyd M.R.
J. Natl. Cancer Inst. 82:1420-1426(1990).
Evidence for thromboxane biosynthesis in established cell lines derived from human lung adenocarcinomas.
Hubbard W.C., Alley M.C., McLemore T.L., Boyd M.R.
Cancer Res. 48:2674-2677(1988).
Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.
Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.
Cancer Res. 48:589-601(1988).
Genetic analysis of indefinite division in human cells: identification of four complementation groups.
Pereira-Smith O.M., Smith J.R.
Proc. Natl. Acad. Sci. U.S.A. 85:6042-6046(1988).
Growth of cell lines and clinical specimens of human non-small cell lung cancer in a serum-free defined medium.
Brower M., Carney D.N., Oie H.K., Gazdar A.F., Minna J.D.
Cancer Res. 46:798-806(1986).
Four human carcinoma cell lines with novel mutations in position 12 of c-K-ras oncogene.
Valenzuela D.M., Groffen J.
Nucleic Acids Res. 14:843-852(1986).
In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors.
Dosik H., Parks W.P.
J. Natl. Cancer Inst. 51:1417-1423(1973).
Heterogeneity in the radiation survival curves and biochemical properties of human lung cancer cell lines.
Mitchell J.B.
J. Natl. Cancer Inst. 73:801-807(1984).
Defective repair of alkylated DNA by human tumour and SV40-transformed human cell strains.
Lubiniecki A.S., Girardi A.J., Galloway S.M., Bynum G.D.
Nature 288:724-727(1980).
High levels of intracellular bombesin characterize human small-cell lung carcinoma.
Moody T.W., Pert C.B., Gazdar A.F., Carney D.N., Minna J.D.
Science 214:1246-1248(1981).
Relationship between karyotype of tissue culture lines and tumorigenicity in nude mice.
Gershwin M.E., Lentz D., Owens R.B.
Exp. Cell Biol. 52:361-370(1984).
Repair of O6-methylguanine in DNA by demethylation is lacking in Mer- human tumor cell strains.
Yarosh D.B., Foote R.S., Mitra S., Day R.S. 3rd
Carcinogenesis 4:199-205(1983).
Distinction of seventy-one cultured human tumor cell lines by polymorphic enzyme analysis.
Wright W.C., Daniels W.P., Fogh J.
J. Natl. Cancer Inst. 66:239-247(1981).
Differential expression of the amv gene in human hematopoietic cells.
Aaronson S.A., Wong-Staal F.
Proc. Natl. Acad. Sci. U.S.A. 79:2194-2198(1982).
Cultured cell lines for research on pulmonary physiology available through the American Type Culture Collection.
Hay R.J., Williams C.D., Macy M.L., Lavappa K.S.
Am. Rev. Respir. Dis. 125:222-232(1982).
Presence of glycogen and growth-related variations in 58 cultured human tumor cell lines of various tissue origins.
Rousset M., Zweibaum A., Fogh J.
Cancer Res. 41:1165-1170(1981).
Secretion of atrial natriuretic peptide and vasopressin by small cell lung cancer.
Lofters W.S., Flynn T.G.
Cancer 75:2442-2451(1995).
Production of gastrin-releasing peptide by a non-small cell lung carcinoma cell line adapted to serum-free and growth factor-free conditions.
Gaither Davis A.L., Cuttitta F.
J. Biol. Chem. 269:8596-8603(1994).
Gene analysis of K-, H-ras, p53, and retinoblastoma susceptibility genes in human lung cancer cell lines by the polymerase chain reaction/single-strand conformation polymorphism method.
Kashii T., Mizushima Y., Monno S., Nakagawa K., Kobayashi M.
J. Cancer Res. Clin. Oncol. 120:143-148(1994).
Inhibitory effects of cholera toxin on in vitro growth of human lung cancer cell lines.
Kiura K., Watarai S., Shibayama T., Ohnoshi T., Kimura I., Yasuda T.
Anticancer Drug Des. 8:417-428(1993).
Insulin-like growth factor expression in human cancer cell lines.";
Grimley C., Battey J., Mulshine J.L., Cuttitta F.
J. Biol. Chem. 271:11477-11483(1996).
HLA-A locus-restricted and tumor-specific CTLs in tumor-infiltrating lymphocytes of patients with non-small cell lung cancer.
Seki N., Hoshino T., Kikuchi M., Hayashi A., Itoh K.
Cell. Immunol. 175:101-110(1997).
CD4+ hepatic cancer-specific cytotoxic T lymphocytes in patients with hepatocellular carcinoma.
Itoh K.
Cell. Immunol. 177:176-181(1997).